<DOC>
	<DOCNO>NCT01610401</DOCNO>
	<brief_summary>In acute myocardial infarction early restoration coronary blood flow effective strategy limit infarct-size . Paradoxically , reperfusion also aggravate myocardial injury contribute final infarct size , process term 'reperfusion injury ' . Ischemia reperfusion ( IR ) -induced endothelial dysfunction seem play pivotal role process , result vasoconstriction reduce blood flow already ischemic tissue . Recently , show glucose-lowering drug metformin able limit IR-injury murine model myocardial infarction , probably increase formation endogenous nucleoside adenosine . In current research proposal , investigator aim translate finding human vivo situation , use flow-mediated dilation ( FMD ) brachial artery well-validated model ( endothelial ) IR-injury .</brief_summary>
	<brief_title>The Metformin-FMD Trial</brief_title>
	<detailed_description />
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Reperfusion Injury</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Caffeine</mesh_term>
	<criteria>Age 3050 year Written inform consent Smoking Hypertension ( supine position : systolic BP &gt; 140 mmHg , diastolic BP &gt; 90 mmHg ) Hyperlipidaemia ( fast total cholesterol &gt; 5.5 mmol/L random &gt; 6.5 mmol/L ) Diabetes Mellitus ( fast glucose &gt; 7.0 mmol/L random glucose &gt; 11.0 mmol/L ) History cardiovascular disease Concomitant use medication Renal dysfunction ( MDRD &lt; 60 ml/min ) Professional athlete</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>